Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Dr. Elsa Bernard
Risk stratification and therapeutic decision-making for myelodysplastic syndromes are based on the International Prognostic Scoring System-Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. The International Working Group for Prognosis in MDS developed and validated the IPSS-Molecular, based on hematologic parameters, cytogenetic abnormalities, and somatic mutations of 31 genes. Compared with the current IPSS-R, IPSS-M improved prognostic discrimination across all clinical end points. The authors derived six IPSS-M risk categories with differences in prognosis.
